Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Long-Term Debt Issuances: 2013-2023

Historic Long-Term Debt Issuances for Viridian Therapeutics, Inc.\DE (VRDN) over the last 6 years, with Dec 2023 value amounting to $15.0 million.

  • Viridian Therapeutics, Inc.\DE's Long-Term Debt Issuances was N/A to $15.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $16.2 million, marking a year-over-year change of. This contributed to the annual value of $15.0 million for FY2023, which is 200.00% up from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Long-Term Debt Issuances of $15.0 million as of FY2023, which was up 200.00% from $5.0 million recorded in FY2022.
  • Viridian Therapeutics, Inc.\DE's Long-Term Debt Issuances' 5-year high stood at $15.0 million during FY2023, with a 5-year trough of $1.7 million in FY2020.
  • Moreover, its 2-year median value for Long-Term Debt Issuances was $10.0 million (2022), whereas its average is $10.0 million.
  • Data for Viridian Therapeutics, Inc.\DE's Long-Term Debt Issuances shows a peak YoY surged of 200.00% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Viridian Therapeutics, Inc.\DE's Long-Term Debt Issuances stood at $1.7 million in 2020, then reached $5.0 million in 2022, then skyrocketed by 200.00% to $15.0 million in 2023.